Birgitte is the Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline, London, UK. She has 17 years of experience from senior positions at Sobi, Amgen, Genzyme and Pharmexa.
Birgitte received her medical degree from the Copenhagen University in Denmark where she also received her PhD. Throughout her industry career Birgitte has led early and late stage development programs across various therapeutic areas. Her experience also includes product commercialization from pre-approval to launch and life cycle management with particular emphasis on medical affairs including evidence generation for value and access, regulatory and safety aspects.
Birgitte has published a number of abstracts and original papers in scientific journals on topics related to biochemical markers of inflammation and connective tissue metabolism in arthritis. She is an external lecturer at Copenhagen University and non-executive board member at Ascendis Pharma.